Clinical Trial: Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone L

Brief Summary: The objective of the study is to investigate whether blood markers can be used to predict the development of bone metastases and to assess the efficacy and safety of zoledronic acid in cancer treatment induced bone loss.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: If and to what extent rising levels of the bone resorption marker CTX can be used as an indicator for the development of bone metastases, diagnosed via bone scintigraphy. [ Time Frame: at 6 months ]

Original Primary Outcome:

Current Secondary Outcome: If and to what extent rising levels of PSA can be used as an indicator for the development of bone metastases [ Time Frame: at 6 months ]

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 13, 2005
Date Started: December 2004
Date Completion:
Last Updated: March 2, 2017
Last Verified: March 2017